Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Met inhibitor tivantinib fails to show survival benefit

Please Note: New Treatments Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

One of the more promising agents for advanced NSCLC in the last few years has been the oral Met inhibitor tivantinib, also known as ARQ-197.  I've described it in some detail in a couple of prior posts, and I was definitely encouraged by the results of the randomized phase II trial of tivantinib with Tarceva (erlotinib) compared with Tarceva alone in Tarceva-naive patients with advanced NSCL which indicated a potentially real survival benefit with the combination for non-squamous patients, and perhaps a particular value for this combination over Tarceva alone for KRAS mutation-positive patients (although this provisional conclusion about KRAS mutation-positive NSCLC was based on a very small number of patients in the phase II trial).

This phase II work led to a large phase III trial called MARQUEE, an approximately 1000-patient global study that I participated in.  Unfortunately, we just received word that the Data Monitoring Committee has reviewed the interim analysis results and recommended that the trial be stopped early, since their analysis led them to conclude that it would not demonstrate a significant difference in overall survival, though it did show a significant improvement in progression-free survival.  This analysis also led to no new safety concerns. 

While this is clearly unwelcome news, I suppose there is still a chance that if the trial demonstrates a survival benefit for patients with KRAS mutation-positive advanced NSCLC for the combination of tivantinib/Tarceva over Tarceva alone, the drug could still have a chance of being further developed for that large subset of NSCLC patients, in whom Tarceva alone is rarely especially effective.   That's probably wishful thinking, but we'll see.

One other question that has come up is whether these results suggest that "MetMAb", or onartuzumab, an antibody against Met, will suffer the same fate.  Onartuzumab has looked very promising for patients with high expression of the Met protein on their tumor cells, and the phase III trial with that agent in combination with Tarceva and compared with Tarceva alone is ongoing.  I don't think the absence of a survival benefit for tivantinib suggest any failure of onartuzumab is more likely: we already know that EGFR tyrosine kinase inhibitors and monoclonal antibodies against EGFR have very different behavior and activity in NSCLC and other cancer types. I wouldn't generalize these negative results and look forward to the completion of the trial with onartuzumab. Let's hope for better results and a new treatment based on that work.

If you were offered participation on a different trial with a Met inhibitor, would you be dissuaded by the findings from the MARQUEE trial?

Next Previous link

Previous PostNext Post

Related Content

Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.
Image
The Importance of Early Detection 2023
Video
Drs. Meredith McKean, Dr. Doug Micalizzi and patient advocate and lung cancer survivor, Ivy Elkins, discuss the importance of early detection and treatment across cancer types, including skin, lung, and breast. To watch the complete playlist click here.

Forum Discussions

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Hi Oaktowngrrl,  Welcome to Grace.  I'm so sorry you're going through this.

 

 Finding a reputable dedicated thoracic surgeon for lung surgery might be difficult, as it is a complex and...

Recent Comments

JOIN THE CONVERSATION
Could you
By Maeve785 on
It sounds like you’re…
By Dr West on
Thank you Janine
By blaze100 on
Hi Blaze,

 

As much as I…
By JanineT GRACE … on